Migraine News and Research

Latest Migraine News and Research

MAP Pharmaceuticals to present new analyses on LEVADEX from FREEDOM-301 Phase 3 clinical trial

MAP Pharmaceuticals, Inc. announced today it will present new analyses from the FREEDOM-301 Phase 3 clinical trial in a late breaker session at the 52nd Annual Scientific Meeting of the American Headache Society (AHS) in Los Angeles, California on Friday, June 25 from 3:30 to 4:00 pm PT. The presentation will show that the Company's investigational LEVADEX™ orally inhaled migraine therapy was effective irrespective of when it was administered during a migraine cycle.

23 Jun 2010

Early adverse experiences influence migraine sufferers' cardiovascular health in adulthood

Migraine sufferers who experienced abuse and neglect as children have a greater risk of cardiovascular (CV) disease including stroke and myocardial infarction (MI) among others, say scientists presenting data at the American Headache Society's 52nd Annual Scientific Meeting in Los Angeles this week.

23 Jun 2010

Researchers find increased activity in visual, auditory and sensorimotor network in migraineurs

Typically, migraine is considered to be an episodic disorder with discrete attacks of headache. But new research by Dr. Till Sprenger and his team from UCSF Headache Group and Technische Universit-t M-nchen found increased network activity -- stronger functional connectivity -- bilaterally in the visual, auditory and sensorimotor network in migraineurs.

23 Jun 2010

Children who experience maltreatment more likely to have frequent headaches as adults, say scientists

Children who experience maltreatment such as emotional, physical and sexual abuse are more likely to experience frequent headaches, including chronic migraine, as adults, say scientists presenting data at the American Headache Society's 52nd Annual Scientific Meeting in Los Angeles this week.

23 Jun 2010

Sleep quality is poor in soldiers with chronic headaches, find researchers

Some 19 percent of soldiers returning from Iraq have migraine and migraine is suspected in another 17 percent. While prevalence of migraine among the U.S. military is well documented , little is known about sleep quality in soldiers with chronic headaches including post-traumatic headache and migraine.

23 Jun 2010

REM sleep deprivation leads to changes in levels of key proteins that increase risk of migraine: Study

Reporting at the American Headache Society's 52nd Annual Scientific Meeting in Los Angeles this week, new research shows that sleep deprivation leads to changes in the levels of key proteins that facilitate events involved in the underlying pathology of migraine.

23 Jun 2010

No increased risk of childhood cancer if born near mobile phone stations: Study

There have been concerns regarding increased risk for cancer in children born to mothers who lived near mobile phone stations during their pregnancy after a report of a cluster of childhood cancer cases near such stations. A newly published study in the British Medical Journal refutes such beliefs and has found no link to early childhood cancers and living near mobile phone masts.

22 Jun 2010

Ferring announces availability of LYSTEDA for cyclic heavy menstrual bleeding in U.S.

Ferring Pharmaceuticals Inc. announced today the U.S. commercial availability of LYSTEDA™ (tranexamic acid) tablets, the only non-hormonal and non-surgical therapy indicated specifically for the treatment of women with cyclic heavy menstrual bleeding (HMB). In clinical studies, LYSTEDA significantly reduced menstrual blood loss (MBL) over three and six cycles of use with the reduction seen as early as the first cycle of use.

21 Jun 2010

NMT Medical receives preliminary results for CLOSURE I PFO/stroke and transient ischemic attack trial

NMT Medical, Inc., an advanced medical technology company that designs, develops, manufactures and markets proprietary implant technologies that allow interventional cardiologists to treat structural heart disease through minimally invasive, catheter-based procedures, today announced that it has received preliminary results for CLOSURE I, its patent foramen ovale (PFO)/stroke and transient ischemic attack (TIA) trial in the U.S.

18 Jun 2010

Bayer sues Teva, Barr in connection with oral contraceptive Gianvi

Today, Bayer HealthCare Pharmaceuticals Inc. and Bayer Schering Pharma AG sued Teva Pharmaceuticals USA, Inc., Barr Pharmaceuticals LLC, and Barr Laboratories, Inc. in the Northern District of Illinois (Chicago) for false advertising and patent infringement in connection with Teva's generic oral contraceptive, Gianvi™. Teva's product is sold as a generic version of Bayer HealthCare's leading oral contraceptive YAZ®.

16 Jun 2010

MAP Pharmaceuticals to present new analyses from LEVADEX Phase 3 trial for acute migraine at 52nd AHS

MAP Pharmaceuticals, Inc. today announced that the Company will present new analyses from the FREEDOM-301 Phase 3 trial of its investigational LEVADEX™ orally inhaled migraine therapy. The post hoc analyses will be presented at the 52nd Annual Scientific Meeting of the American Headache Society (AHS) in Los Angeles, California.

10 Jun 2010

MonoSol Rx, APR expand film formulation development collaboration

MonoSol Rx, the developer of PharmFilm® technology and a drug delivery company specializing in proprietary pharmaceutical film products, and APR Applied Pharma Research s.a. ("APR") announced today an expansion of their relationship to identify and develop film formulations of prescription drug products beyond ondansetron and donepezil to include zolmitriptan. Zolmitriptan is currently commercially available for the acute treatment of migraine headache in adults, and facing initial patent expirations in 2012.

10 Jun 2010

Mutations in ion channels cause rare inherited pain disorder: Research

A mutation that enhances the function of a specific ion channel has been identified as the cause of a rare inherited pain disorder. The research, published by Cell Press in the June 10 issue of the journal Neuron, proposes a potential treatment for the disorder and may lead to a better understanding of chronic pain in humans.

10 Jun 2010

CoLucid's lasmiditan NAAMA effective in treatment of acute migraine attacks

CoLucid Pharmaceuticals, Inc.,, an innovative biotechnology company focusing on therapies for central nervous system disorders, today announced that its investigational first-in-class Neurally Acting Anti-Migraine Agent (NAAMA), lasmiditan (also known as COL-144), a selective 5-HT1F receptor agonist, was effective when given orally to treat acute migraine attacks, as documented in a Phase IIb study.

10 Jun 2010

Endo, Penwest announce settlement of OPANA ER litigation with Impax

Endo Pharmaceuticals and Penwest Pharmaceuticals announced today that the companies have settled litigation with Impax Laboratories, Inc. regarding the production and sale of generic formulations of OPANA® ER (oxymorphone hydrochloride) Extended Release tablets.

9 Jun 2010

Clinical trial data of XP19986, XP13512 to be presented at Associated Professional Sleep Society meeting

XenoPort announced today that data from clinical trials of its product candidates arbaclofen placarbil and XP13512 (gabapentin enacarbil) will be presented at the Associated Professional Sleep Society meeting in San Antonio, Texas.

7 Jun 2010

Alcohol consumption, cigarette smoking associated with teen migraines, TTH : Study

A novel study by German researchers reported that alcohol consumption and cigarette smoking were associated with increased migraines and tension-type headaches in high school students. Coffee drinking and physical inactivity were associated specifically with migraines. Results of this study, the first to investigate modifiable risk factors for different types of headaches in a youth population, appear online early in Headache, a journal published by Wiley-Blackwell on behalf of the American Headache Society.

7 Jun 2010

St. Jude Medical's Epiducer lead delivery system for neurostimulation therapy receives CE Mark approval

St. Jude Medical, Inc., a global medical device company, today announced European CE Mark approval of its new Epiducer™ lead delivery system for neurostimulation therapy. Unveiled at the Neurosurgery 2010 Congress in Lyon, France, the Epiducer lead delivery system is the first of its kind, allowing introduction of S-Series perc-paddle leads as well as multiple lead arrays through a single percutaneous entry point.

27 May 2010

BDSI partners with Kunwha to develop and commercialize BEMA Fentanyl in Republic of Korea

BioDelivery Sciences International, Inc. announced that it has entered into a license and supply agreement with Kunwha Pharmaceutical Co., Ltd., for the exclusive rights to develop and commercialize BEMA Fentanyl (marketed as ONSOLIS in the U.S.) in the Republic of Korea. The agreement results in potential milestone payments to BDSI of up to $1,275,000, which includes an upfront payment of $300,000. In addition, BDSI will receive an ongoing royalty based on net sales.

27 May 2010

Aradigm reports total revenue of $4.0M for first-quarter 2010

Aradigm Corporation today announced financial results for the first quarter and three months ended March 31, 2010.

13 May 2010

Migraine News and Research

Latest Migraine News and Research

MAP Pharmaceuticals to present new analyses on LEVADEX from FREEDOM-301 Phase 3 clinical trial

Early adverse experiences influence migraine sufferers' cardiovascular health in adulthood

Researchers find increased activity in visual, auditory and sensorimotor network in migraineurs

Children who experience maltreatment more likely to have frequent headaches as adults, say scientists

Sleep quality is poor in soldiers with chronic headaches, find researchers

REM sleep deprivation leads to changes in levels of key proteins that increase risk of migraine: Study

No increased risk of childhood cancer if born near mobile phone stations: Study

Ferring announces availability of LYSTEDA for cyclic heavy menstrual bleeding in U.S.

NMT Medical receives preliminary results for CLOSURE I PFO/stroke and transient ischemic attack trial

Bayer sues Teva, Barr in connection with oral contraceptive Gianvi

MAP Pharmaceuticals to present new analyses from LEVADEX Phase 3 trial for acute migraine at 52nd AHS

MonoSol Rx, APR expand film formulation development collaboration

Mutations in ion channels cause rare inherited pain disorder: Research

CoLucid's lasmiditan NAAMA effective in treatment of acute migraine attacks

Endo, Penwest announce settlement of OPANA ER litigation with Impax

Clinical trial data of XP19986, XP13512 to be presented at Associated Professional Sleep Society meeting

Alcohol consumption, cigarette smoking associated with teen migraines, TTH : Study

St. Jude Medical's Epiducer lead delivery system for neurostimulation therapy receives CE Mark approval

BDSI partners with Kunwha to develop and commercialize BEMA Fentanyl in Republic of Korea

Aradigm reports total revenue of $4.0M for first-quarter 2010

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Migraine News and Research

Latest Migraine News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in